Results 71 to 80 of about 9,731 (238)
Expressions of Interleukin-4 and Interleukin-5 in Nodular Prurigo and Pruritic Papular Lesions
Folia Medica IndonesianaHighlights: 1. An examination of IL-4 and IL-5 expressions in nodular prurigo and pruritic papular eruption is crucial for enhancing the effectiveness of biological agent therapy, specifically for HIV/AIDS patients. 2.
Ayu Wikan Sayekti +3 more
doaj +1 more source
De Novo HIV Infection Diagnoses in a Department of Dermatology and Venereology in Lisbon, Portugal [PDF]
, 2016 BACKGROUND: Portugal has the highest prevalence rate of HIV infection in Western Europe. The proportion of patients with a late diagnosis, carried out in full-blown AIDS stage, remains high.
Brasileiro, A +6 more
core +1 more source
Open Life Sciences, 2019 AbstractPrurigo pigmentosa (PP) is an inflammatory dermatosis with unknown etiology. The clinical presentations of PP varies according to the stages of the disease. Rarely, the formation of numerous vesicles and bullae upon erythematous infiltrative plaques can be found during the entire clinical course. In the present case, a 29-year-old Chinese woman
Wang Xinjun, Xu Chenchen
openaire +4 more sources
Dementia Incidence in Patients With Prurigo Nodularis: An Observational Retrospective Cohort Study
JEADV Clinical Practice, EarlyView.
Madison P. Olexson +3 more
wiley +1 more source
International Journal of Dermatology, EarlyView.ABSTRACT Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder characterized by hyperkeratotic nodules and a debilitating itch–scratch cycle. Conventional therapies have limited efficacy and safety issues, while biologics have recently emerged as a promising alternative.
Andrea Lancz +7 more
wiley +1 more source
Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review
International Journal of Dermatology, EarlyView.ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska +8 more
wiley +1 more source
International Journal of Dermatology, EarlyView.ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo +11 more
wiley +1 more source
Classifying atopic dermatitis: protocol for a systematic review of subtypes (phenotypes) and associated characteristics. [PDF]
, 2018 INTRODUCTION: Atopic dermatitis is a complex disease with differing clinical presentations. Many attempts have been made to identify uniform subtypes, or phenotypes, of atopic dermatitis in order to identify different aetiologies, improve diagnosis ...
Abuabara, Katrina +6 more
core +2 more sources
Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review
Journal of the European Academy of Dermatology and Venereology, EarlyView.Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta +5 more
wiley +1 more source
Therapeutic advances in pruritus as a model of personalized medicine
Journal of the European Academy of Dermatology and Venereology, EarlyView.Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung +2 more
wiley +1 more source